Genesis Therapeutics Secures $200M Series B Funding for AI Drug Discovery and Clinical Testing
TL;DR Summary
Genesis Therapeutics has raised $200 million in Series B financing, co-led by Andreessen Horowitz and an anonymous life science investor. The startup, which utilizes artificial intelligence to design small molecule drugs, plans to use the funds to further develop its AI technologies, expand its pipeline, and advance its first computer-generated drugs into clinical studies.
Topics:business#ai-drug-discovery#andreessen-horowitz#biotechnology#clinical-studies#genesis-therapeutics#series-b-financing
- Genesis Therapeutics raises $200M for AI drug discovery based on Stanford research Endpoints News
- Genesis Therapeutics Closes Oversubscribed $200 Million Series B Business Wire
- Genesis Therapeutics Closes $200M Series B Funding FinSMEs
- AI drug designer Genesis Therapeutics forges $200M round with eye on clinical testing FierceBiotech
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
0 min
vs 1 min read
Condensed
55%
121 → 54 words
Want the full story? Read the original article
Read on Endpoints News